158 related articles for article (PubMed ID: 27476290)
1. PHARMACEUTICAL QUALITY OF GENERIC ATORVASTATIN PRODUCTS COMPARED WITH THE INNOVATOR PRODUCT: A NEED FOR REVISING PRICING POLICY IN PALESTINE.
Shawahna R; Hroub AK; Abed E; Jibali S; Al-Saghir R; Zaid AN
Acta Pol Pharm; 2016; 73(3):725-30. PubMed ID: 27476290
[TBL] [Abstract][Full Text] [Related]
2. Quality assessment of different brands of atorvastatin tablets available in Riyadh, Saudi Arabia.
AlMuhsin A; Ahad A; Bin Jardan YA; Raish M; Ahmad A; Alkharfy KM; Al-Jenoobi FI
BMC Pharmacol Toxicol; 2022 Sep; 23(1):69. PubMed ID: 36100946
[TBL] [Abstract][Full Text] [Related]
3.
Abou-Taleb BA; Megallaa MH; Khalafallah NM; Khalil SH
Drug Dev Ind Pharm; 2020 Feb; 46(2):192-199. PubMed ID: 31937146
[TBL] [Abstract][Full Text] [Related]
4. Interchangeability between paracetamol tablets marketed in Palestine. Is there a quality reason for a higher price?
Zaid A; Rinno T; Jaradat N; Jodeh S; Khammash S
East Mediterr Health J; 2013 Jun; 19(6):542-6. PubMed ID: 24975183
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the In-Vitro Dissolution Permeation Systems 1 (IDAS1) as a potential tool to monitor for unexpected changes in generic medicaments in poorly regulated markets.
Rodriguez N; Grosso M; Galvez B; Calderon G; Lau L; Turner VA; Hidalgo IJ
Eur J Pharm Sci; 2021 Jun; 161():105791. PubMed ID: 33691154
[TBL] [Abstract][Full Text] [Related]
7. Investigation of Biowaivers for Immediate Release Formulations Containing BCS III Drugs, Acyclovir, Atenolol, and Ciprofloxacin Hydrochloride, Using Dissolution Testing.
Reddy NH; Patnala S; Kanfer I
AAPS PharmSciTech; 2017 Feb; 18(2):424-431. PubMed ID: 27038483
[TBL] [Abstract][Full Text] [Related]
8. Quality and efficiency of statin prescribing across countries with a special focus on South Africa: findings and future implications.
Godman B; Bishop I; Campbell SM; Malmström RE; Truter I
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):323-30. PubMed ID: 25338546
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®.
Gasser UE; Fischer A; Timmermans JP; Arnet I
BMC Pharmacol Toxicol; 2013 Apr; 14():24. PubMed ID: 23617953
[TBL] [Abstract][Full Text] [Related]
10. In vitro disintegration studies of weekly generic and branded risedronate sodium formulations available in Canada.
Walker AD; Adachi JD
Curr Med Res Opin; 2011 Sep; 27(9):1749-54. PubMed ID: 21781014
[TBL] [Abstract][Full Text] [Related]
11. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
Roughead EE; Kim DS; Ong B; Kemp-Casey A
WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
[TBL] [Abstract][Full Text] [Related]
12. Comparison of simvastatin tablets from the US and international markets obtained via the Internet.
Veronin MA; Nguyen NT
Ann Pharmacother; 2008 May; 42(5):613-20. PubMed ID: 18413690
[TBL] [Abstract][Full Text] [Related]
13. Influence of Prosolv and Prosolv:Mannitol 200 direct compression fillers on the physicomechanical properties of atorvastatin oral dispersible tablets.
Gowda V; Pabari RM; Kelly JG; Ramtoola Z
Pharm Dev Technol; 2015 Jun; 20(4):394-400. PubMed ID: 24397821
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical equivalency of locally and regionally manufactured generic pharmaceutical products in UAE.
Al Ali L; Jagal J; Joseph J; Ahmed IS; Rawas-Qalaji M
Saudi Pharm J; 2022 Sep; 30(9):1243-1251. PubMed ID: 36249940
[TBL] [Abstract][Full Text] [Related]
15. [In vitro and in vivo biopharmaceutical evaluation of lorazepam commercial tablets].
Giannone I; Musumeci T; Pecora TM; Puglisi G
Clin Ter; 2005; 156(5):197-201. PubMed ID: 16382968
[TBL] [Abstract][Full Text] [Related]
16. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the pharmaceutical quality of marketed enteric coated pantoprazole sodium sesquihydrate products.
Mostafa HF; Ibrahim MA; Mahrous GM; Sakr A
Saudi Pharm J; 2011 Apr; 19(2):123-7. PubMed ID: 23960750
[TBL] [Abstract][Full Text] [Related]
18. [Trends in the quality evaluation of generic products and bioequivalence guidelines].
Yomota C
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2012; (130):1-12. PubMed ID: 23243982
[TBL] [Abstract][Full Text] [Related]
19. Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms.
Meredith PA
Curr Med Res Opin; 2009 Sep; 25(9):2179-89. PubMed ID: 19601710
[TBL] [Abstract][Full Text] [Related]
20. A survey of the quality of generic clarithromycin products from 18 countries.
Nightingale CH
Clin Drug Investig; 2005; 25(2):135-52. PubMed ID: 17523763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
